


Patients first. No small plans. Take care of each other. These are the guiding principles that form the ethos of Inari Medical. We are committed to improving lives in extraordinary ways by creating innovative solutions for both unmet and underserved health needs. In addition to our purpose-built products, we leverage our capabilities in education, clinical research, and program development to improve patient outcomes. We are passionate about our mission to establish our treatments as the standard of care for venous thromboembolism and beyond. We are just getting started.

A mission, a plan, and crisp execution producing sustained growth


- ▶ **Purpose Built, Highly Differentiated Toolkits** designed to solve specific problems
- ▶ **6 Large and Underpenetrated Markets** (>\$20B in Total Global TAM, + ~\$10B US Prevalence)*
- ▶ **Robust Pipeline of Innovation** (14 products launched 2021-2023)**
- ▶ **7 Leading Clinical Studies** (3 Randomized Control Trials Underway, 450+ peer-reviewed publications)**
- ▶ **1,300 Employees** and Growing
- ▶ **Efficient Procedures, Favorable Economics** driven by limited hospital resources, avoiding ICU stay, and reducing total length of stay

Large US addressable markets totaling ~ \$10B across 6 disease states



FINANCIAL PROFILE

Robust quarterly revenue growth with gross margins of >80%
REVENUES
(LAST 8 QUARTERS, \$ IN MILLIONS)



***Based on third party data and Inari management estimates

***FLARE, FLASH, FLAME, CLOUT, PEERLESS RCT, PEERLESS II RCT, DEFIANCE RCT

*** Products launched 2021: Triever20 Curve catheter, FlowTriever2 catheter, FlowStasis, FlowSaver, Triever24 Flex catheter; 2022: ClotTriever BOLD catheter, Intri24 sheath, Protrieve sheath, InThrive system, Triever Gen 4 catheters; 2023: Triever 16 Curve catheter, RevCore, ClotTriever XL catheter, ClotTriever BOLD Gen 2 catheter

1. "Pulmonary Embolism in 2017: Increasing Options for Increasing Incidence", National Center for Biotechnology Information, May 2017.

2. PERT Consortium® Registry Data. Interim results on 5,048 Patients presented at PERT Symposium October 20217.

3. Schultz J, et al. Pulm Circ. 2019 Jan 11;9(3):2045894018824563.8. Chopard et al. 2017.

4. Sista AK, et al. Vasc Med. 2017 Feb;22(1):37-43

4.1 Am J of Cardiol. Volume 119, Issue 11, 1883-1889.

4.2 Miniati et al. 2006 Medicine. 85: 253-62. 10.1097/01.md.0000236952.87590.c810.Mrozek et al. Biomed Pap Med Fac Univ Palacky Olomouc Czech

4.3 Repub. 2018 162(2):121-126. doi: 10.5507/bp.2018.00111.

5. Kahn, Susan R. Hematology Am Soc Hematol Educ Program. 2016 Dec 2; 2016(1): 413-418

6. Young et al., Post-treatment residual thrombus increases the risk of recurrent deep vein thrombosis and mortality. J Thromb Haemost 2006; 4: 1919-24.

CONTACT INFORMATION

- 📍 6001 Oak Canyon, Ste.100, Irvine, CA 92618, USA
- 📍 Messeplatz 10, 4058 Basel, Switzerland
- @ info@inarimedical.com
- 🌐 inarimedical.com

(NASDAQ: NARI)